Zenotech Laboratories share price
BSE: 532039Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹39.50.
- Next results date: the board meets on 28 Oct 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹246 Cr2,190th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 Apr 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 28 Jul 2026
- −2.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 28 Jul 2026
- −3.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 Apr 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,902
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 28 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹9.60 Crup 8.25%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.46 CrQuarter to Mar 2026: −₹3.15 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −4.7%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
The years either side of a change of basis do not compare. From the year to Mar 2021, the company's revenue for that year, ₹22 Cr, differs from its quarters added, ₹20 Cr. From the year to Mar 2022, the company's revenue for that year, ₹37 Cr, differs from its quarters added, ₹35 Cr. From the year to Mar 2024, the company's revenue for that year, ₹37 Cr, differs from its quarters added, ₹38 Cr.
| ₹ crore | Sep 2024Filed 29 Oct | Dec 2024Filed 28 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 28 Jul | Sep 2025Filed 31 Oct | Dec 2025Filed 23 Jan | Mar 2026Filed 29 Apr | Jun 2026Filed 28 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.7 | 10.2 | 11.1 | 8.6 | 10.2 | 11.8 | 8.9 | 9.6 |
| Net profit | 1.3 | 1.7 | 1.2 | 1.0 | −0.8 | 1.9 | −3.2 | −0.5 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 15.4% | 16.6% | 11.1% | 11.5% | −8.2% | 16.3% | −35.5% | −4.7% |
Business segments
In the year to Mar 2026 the company reports one business segment, Manufacture of Pharmaceutical products, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the years to Mar 2021, Mar 2022 and Mar 2024: days before it are of the company before the change.PE ratio and valuation history
At or below today's level on 4% of 1,972 trading days since Nov 2018.
At or below today's level on 84% of 1,790 trading days since Aug 2019.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −34.0% | – | – | 0.0% |
| 3 years | −10.0% | – | – | 0.0% |
| 5 years | −0.4% | – | – | 0.0% |
Peers and competitors
Pharmaceuticals, 215 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Zenotech Laboratories in market cap. 1 company in the table last traded before then: its row is priced on its last trade. 1 company in its own group left out: one owns more than half of the other, directly or through a company it controls, or one owner more than half of both.
Zenotech Laboratories is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Astonea LabsASTONEALAB | 340 | 75.2 | 5.9 | – | – | – | 12.0% | – | 0.00% |
 Lyka LabsLYKALABS | 293 | – | 3.2 | – | −2.6% | – | −9.2% | −8.0% | 0.00% |
 Astal LaboratoriesASTALLTD | 279 | 28.7 | 0.9 | 19.3 | +122.7% | +4.4% | 5.4% | 4.2% | 0.00% |
 Ambalal Sarabhai EnterprisesAMBALALSA | 266 | 19.6 | 1.7 | 20.1 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 BDH IndustriesBDH | 244 | 20.8 | 3.2 | 14.2 | +44.8% | +22.9% | 16.1% | 18.2% | 1.18% |
 Everest OrganicsEVERESTO | 222 | 42.2 | 2.9 | 13.8 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Gennex LaboratoriesGENNEX | 211 | 11.5 | 0.9 | 9.1 | +24.1% | +7.3% | 9.0% | 7.0% | 0.00% |
 Sat Kartar LifeSATKARTAR | 206 | 12.0 | 3.0 | – | – | – | 28.7% | – | 0.54% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
19 Oct · Board meeting
Meeting on 28 Oct 2026: quarterly results
Sep 2026
Aug 2026
Zenotech Laboratories share price by year
Each calendar year to 2025.Zenotech Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 46.19 | −35.8% | 71.59 | 44.23 |
| 2024 | 71.99 | +8.1% | 101.67 | 56.47 |
| 2023 | 66.58 | +2.7% | 74.70 | 45.94 |
| 2022 | 64.80 | +6.1% | 74.20 | 45.10 |
| 2021 | 61.05 | +59.6% | 62.25 | 29.85 |
| 2020 | 38.25 | +47.1% | 38.45 | 12.55 |
| 2019 | 26.00 | −31.3% | 37.30 | 14.70 |
| 2018 | 37.85 | −17.9% | 51.35 | 32.80 |
| 2017 | 46.10 | +21.8% | 61.65 | 36.85 |
| 2016 | 37.85 | −25.1% | 60.50 | 32.10 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 39.99 | 40.80 | 39.02 | 40.31 | 40.52 | 3,902 |
| 22 Oct 2026 | 41.50 | 41.79 | 39.50 | 39.50 | 39.95 | 16,200 |
| 21 Oct 2026 | 42.75 | 42.76 | 41.00 | 41.05 | 41.71 | 7,458 |
| 19 Oct 2026 | 42.01 | 43.40 | 42.01 | 42.89 | 42.60 | 1,129 |
| 16 Oct 2026 | 43.95 | 43.95 | 43.00 | 43.06 | 43.13 | 1,174 |
| 15 Oct 2026 | 42.75 | 44.25 | 41.80 | 43.95 | 43.25 | 7,862 |
| 14 Oct 2026 | 43.50 | 44.00 | 42.57 | 43.50 | 43.62 | 2,543 |
| 13 Oct 2026 | 42.25 | 44.00 | 41.50 | 43.66 | 43.06 | 4,093 |
| 12 Oct 2026 | 42.26 | 43.40 | 42.25 | 42.25 | 42.68 | 4,170 |
| 9 Oct 2026 | 41.62 | 43.50 | 41.10 | 43.07 | 42.32 | 14,643 |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 1 Jun 2017 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Company details
- Legal name
- Zenotech Laboratories Limited
- BSE code
- 532039
- ISIN
- INE486F01012
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 1996
- Face value
- ₹10
- CIN
- L27100TG1989PLC010122
- Corporate identity number, the registrar of companies' code for it